Leukemia & lymphoma/Leukemia and lymphoma · 2018 · 10 citations · 30 references
MedicineHematologyOncologyCell TherapyStem Cell TransplantationTransplant ImmunologyAllogeneic Stem Cell TransplantationDonor MatchingGraft-versus-host DiseaseTransplant OutcomesAllogeneic Stem Cell TherapyGraft-versus-host Disease-related SurvivalRecurrence-free SurvivalRefractory Hodgkin LymphomaRelapsed Hodgkin LymphomaSurvival After Allogeneic TransplantationTransplantation For Hematologic MalignanciesTransplantation Outcome Assessment
This monocentric retrospective study included 70 consecutive relapsed/refractory Hodgkin lymphoma (RR-HL) patients receiving reduced-intensity allogeneic stem cell transplantation (alloSCT). We evaluated overall and progression-free survival (OS, PFS), graft-versus host disease/relapse-free survival (GFRS), and chronic GVHD-free OS (cGVHD-free OS) defined as OS without moderate-to-severe cGVHD. Patients had a median age of 33 years (range, 18-60 years), 23% had refractory disease (SD/PD). Donors were HLA identical (39%), unrelated (30%), or haploidentical (31%). Median follow-up was 6.2 years. Five-year OS was 59% and PFS was 49%. NRM was 16% at 1 year. 44% of patients had cGVHD, and 14% moderate-to-severe cGVHD at last follow-up. GFRS and cGVHD-free OS were 26 and 48% at 5 years. In multivariate analysis, resistant disease at alloSCT impacted survival and GFRS. In conclusion, disease response before alloSCT impacts survival and GFRS. GVHD outcomes may help comparing the long-term effects of the new salvage treatments that bridge patients to alloSCT.
30